Joshua Brody, Director of Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai, shared a post on LinkedIn:
“One of the most transformative changes in lymphoma immunotherapy is ‘not’ a large randomized trial.
It’s the incremental progress that let’s us now treat DLBCL patients with bispecifics in the clinic without need for hospitalization.”
Other articles about immunotherapy on OncoDaily.